Retatrutide Dosage: TRIUMPH-1 Escalation Ladder + Clinical Evidence

At a glance

• TRIUMPH-1 dose ladder: 2 mg → 4 mg → 6 mg → 9 mg → 12 mg, escalated every 4 weeks once-weekly subcutaneous. The trial-design paper (Giblin 2026 Diabetes Obes Metab) is the peer-reviewed anchor for this schedule^[1].
• Time to each dose from a 2 mg start: 4 mg at week 4, 6 mg at week 8, 9 mg at week 12, 12 mg at week 16 (first 12 mg dose). Patients are typically considered to have reached steady-state at the max dose around 20 weeks — one full 4-week interval at 12 mg.
• Phase 2 dose-response (Jastreboff 2023 NEJM): mean total body weight loss at 48 weeks was −7.2% at 1 mg, −17.5% at 4 mg, −22.8% at 8 mg, and −24.2% at 12 mg — the largest dose-ranging pharmacological weight loss reported in a controlled obesity trial at the time of publication^[3].
• Why escalate at all: nausea, vomiting, and diarrhea concentrate during the early weeks of any GLP-1 or GIP/GLP-1/glucagon agonist. The 4-week intervals between dose steps were chosen so the GI receptor signal can desensitize partially before the next step. Compressed schedules in phase 2 produced unacceptable GI-driven discontinuation.
• Comparator cadences are similar: tirzepatide (Zepbound, SURMOUNT-1) escalates 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg over 20 weeks^[4]; semaglutide (Wegovy, STEP-1) escalates 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg over 16 weeks^[5]. Triple-agonism does not buy faster titration.
• Pre-approval caveat: retatrutide is not FDA- approved as of May 2026. The final prescribing dose schedule will be set when the FDA approves the New Drug Application (Lilly investor guidance: NDA filing late 2026 / early 2027). Trial dosing in TRIUMPH-1 may differ from FDA-approved dosing once issued.

The TRIUMPH-1 dose ladder, step by step

Retatrutide (Eli Lilly LY3437943) is a once-weekly subcutaneous injection that activates three incretin and glucagon receptors simultaneously — GIP, GLP-1, and glucagon — making it the first triple-agonist in late- stage clinical development for chronic weight management. The TRIUMPH-1 phase 3 obesity registration trial (NCT05929066), described in detail in the design paper by Giblin and colleagues^[1], uses a 5-step escalation ladder spaced at 4-week intervals.

A patient who tolerates each step reaches the maximum 12 mg dose at the start of week 17 and completes one full 4-week interval at 12 mg by week 20. The TRIUMPH-1 protocol allows prescribers to down-titrate at any step if GI symptoms become intolerable, with re-escalation attempts permitted after symptoms resolve. The trial's primary endpoint is mean percent change in body weight from baseline at the 80-week timepoint.

Why escalation is required — the GI tolerability story

The mechanism that makes retatrutide effective is the same mechanism that drives its side effects. Activating GLP-1 and GIP receptors slows gastric emptying and suppresses appetite; in the gut, these receptor signals also drive the gastrointestinal adverse events (GI AEs) that show up as nausea, vomiting, diarrhea, constipation, and occasional early satiety to the point of food aversion. These are on-target effects, not off-target toxicity.

The 4-week interval between dose steps is not arbitrary. The phase 2 dose-finding trial^[3] tested both faster and slower escalation schedules and converged on 4-week steps as the cadence at which the receptor signal can partially desensitize before the next step is attempted. Compressed schedules — 2-week steps or starting above 2 mg — produced unacceptable GI-driven treatment discontinuation. Slower schedules delayed clinical benefit without measurable safety gain.

In phase 2, GI AEs were the most common adverse events at every dose, were mostly mild-to-moderate, and were concentrated during the titration weeks rather than the maintenance phase. The pattern is familiar to anyone who has prescribed semaglutide or tirzepatide: most patients adapt within 1–2 weeks of each step, and the few patients who do not adapt are the ones who benefit from down-titration or a slower individualized schedule. For background on the GI mechanism across the class, see our review of GLP-1 constipation and GLP-1 sulfur burps and reflux.

Adverse event rates by dose — what phase 2 showed

The phase 2 trial (n=338) is the most granular dose-by-dose safety dataset publicly available for retatrutide in obesity^[3]. TRIUMPH-1 pivotal AE data are guided to publication in 2026 but were not yet PubMed-indexed at this article's publication date; the phase 2 numbers are the best available approximation of what to expect at each TRIUMPH-1 dose tier.

The pattern is the same across every GLP-1 / GIP-GLP-1 / triple-agonist phase 3 trial: GI AE rates rise with dose, the majority are mild-to-moderate at every dose, and overall discontinuation rates remain in the single digits to low teens. For comparison, SURMOUNT-1 tirzepatide 15 mg reported ~33% nausea and ~7% discontinuation due to AEs^[4]; STEP-1 semaglutide 2.4 mg reported ~44% nausea and ~7% discontinuation due to AEs^[5]. The retatrutide 12 mg discontinuation rate is in the same range as semaglutide and tirzepatide pivotal trials, despite the higher overall body weight loss.

TRIUMPH-1 obesity readouts (and the OSA and knee-OA substudies described in the Giblin design paper) will refine these numbers in the 80-week setting. The pattern is unlikely to change qualitatively — titration matters, GI events concentrate early, and most patients can tolerate the full ladder when escalated at 4-week intervals.

TBWL by dose — the efficacy gradient at week 48

Phase 2 weight-loss outcomes from the Jastreboff 2023 NEJM trial^[3] are the clearest publicly available retatrutide dose-response data. The 48-week mean total body weight loss (TBWL) scaled monotonically with dose, with the 12 mg arm producing the largest weight loss ever reported in a pharmacological obesity trial up to that publication.

TRIUMPH-1 extends the primary outcome to 80 weeks. The expectation, based on the trajectory in tirzepatide (SURMOUNT-1: −15.0% at 5 mg / −19.5% at 10 mg / −20.9% at 15 mg over 72 weeks)^[4] and semaglutide (STEP-1: −14.9% at 2.4 mg over 68 weeks)^[5], is that retatrutide's 12 mg arm will extend its phase 2 gradient further with continued weight loss between weeks 48 and 80 rather than plateauing. The TRIUMPH-1 design paper is explicit that the trial is powered to detect both the magnitude of weight loss and the durability through 80 weeks^[1].

For lipid and metabolic effects at each dose, see the Pearson 2026 J Clin Endocrinol Metab substudy^[2] — triglyceride and apoB reductions also scaled with dose, with the largest effects at 12 mg, consistent with the additional hepatic and energy-expenditure effects of glucagon receptor activation that distinguish retatrutide from semaglutide-class and tirzepatide-class agonists.

How retatrutide escalation compares to tirzepatide and semaglutide

All three modern weekly-injectable obesity medications reach their maximum dose in roughly the same window: 16 to 20 weeks of weekly injection. None can be safely escalated faster because the rate-limiting factor — GI tolerability — is biologically conserved across the class.

Three observations stand out:

• 4-week intervals are class-standard. Every modern GLP-1 / GIP-GLP-1 / GIP-GLP-1-glucagon agonist for chronic weight management uses 4-week step intervals. Faster has been tested and failed on tolerability; slower delays clinical benefit without safety gain.
• Retatrutide's ladder has fewer steps than tirzepatide's. Tirzepatide has 6 steps (2.5/5/7.5/10/12.5/15); retatrutide has 5 (2/4/6/9/12). Both reach max in ~20 weeks. The retatrutide step sizes (especially the 6 → 9 mg and 9 → 12 mg jumps) are proportionally larger than tirzepatide's 2.5 mg increments. Whether this matters in the real-world setting will be quantified once TRIUMPH-1 detailed tolerability tables are published.
• Semaglutide reaches max one step faster. STEP-1 used a 16-week ladder (5 steps over 16 weeks); the others use 20 weeks (5 or 6 steps). The semaglutide max dose (2.4 mg) is much lower in absolute terms because the drug is a high-affinity single-receptor agonist with a much longer half-life and different dose-response curve.

For the head-to-head efficacy comparison between approved molecules, see our Wegovy vs Ozempic evidence review and the cross-class discussion in the GLP-1 trial results quarterly roundup.

Caveat — FDA label may differ from trial dosing

Retatrutide is not FDA-approved as of May 2026. This article describes the dose ladder used in the TRIUMPH-1 registration trial. The final dosing schedule will be set in Section 2 of the package insert when the FDA approves Eli Lilly's New Drug Application. Per Lilly investor guidance, NDA submission is targeted for late 2026 / early 2027; FDA action would follow 10–12 months later under priority or standard review.

Trial dosing and approved dosing can differ in three common ways:

1. The FDA may approve a subset of doses. Tirzepatide phase 2 tested doses up to 15 mg and 15 mg was ultimately approved, but the FDA could have constrained the approval to the lower three or four doses if the dose-response or safety margin had warranted. The FDA retains this discretion for retatrutide.
2. The label may modify the escalation cadence. Section 2 of any obesity-drug label specifies titration intervals and dose-adjustment options. The FDA can extend the interval (e.g., 8-week steps instead of 4-week) if AE data warrant, or shorten it if early-phase tolerability improvements support faster titration.
3. The label may add dose-adjustment criteria. GFR thresholds, hepatic-impairment dose adjustments, interactions with insulin or sulfonylureas, and dose-adjustment guidance for missed doses are all set at approval. None of this is currently public for retatrutide.

Until FDA approval, retatrutide is not legally available outside the TRIUMPH program. It is not eligible for FDA 503A or 503B compounding — there is no USP/NF monograph, it is not on the FDA bulk-drug substances list for 503B, and it is not on the FDA drug shortage list. Multiple FDA Warning Letters have been issued in 2025 to compounders distributing retatrutide outside the approved supply chain. Patients seeking retatrutide today have two legitimate options: enroll in an open TRIUMPH substudy, or wait for FDA approval. For the access timeline and the FDA enforcement context, see our retatrutide approval and access timeline.

When patients typically reach the maximum dose

For a patient starting at 2 mg on day 1, the timeline through the TRIUMPH-1 ladder is:

• Week 4 (end of step 1): escalate to 4 mg. The first dose at 4 mg is given at the start of week 5.
• Week 8 (end of step 2): escalate to 6 mg.
• Week 12 (end of step 3): escalate to 9 mg.
• Week 16 (end of step 4): escalate to 12 mg — the first 12 mg dose is given at the start of week 17.
• Week 20: the patient has completed one full 4-week interval at 12 mg. This is typically when steady-state at the maximum dose is considered established.

In TRIUMPH-1, patients who cannot tolerate escalation can either hold at a lower dose or down-titrate one step, with re-escalation attempts permitted after symptoms resolve. The proportion of patients who reach 12 mg within ~20 weeks without down-titration is one of the secondary endpoints of the trial; phase 2 reported that the majority of patients randomized to the 12 mg arm reached the maximum dose, with a minority requiring a slower individualized titration.

Real-world equivalent timing in clinical practice (once approved) will depend on the final labeled cadence, on insurance step-edit rules, and on individual GI tolerability. The post-approval analogs are tirzepatide and semaglutide, where the real-world ramp-up commonly takes 4–6 months rather than the trial-protocol 4–5 months because of pharmacy supply gaps, insurance prior-authorization delays, and patient-driven slower titration for side-effect comfort.

Verdict

The TRIUMPH-1 retatrutide dose ladder is a 5-step escalation from 2 mg to 12 mg weekly subcutaneous in 4-week increments, reaching the maximum dose at about week 17 and steady-state at week 20. The cadence is consistent with tirzepatide and semaglutide ladders — GI tolerability remains the rate-limiting step across the class, and triple-agonism does not buy faster titration. Phase 2 data show that the weight- loss efficacy gradient scales with dose (−8.7% at 4 mg to −24.2% at 12 mg over 48 weeks), with AE rates also scaling with dose but the majority of TEAEs remaining mild- to-moderate and concentrating during the titration window.

The most important caveat is that retatrutide is not FDA-approved as of May 2026. This article reflects the TRIUMPH-1 protocol, not a final FDA label. Final Section 2 dosing — the constraint that will actually govern real-world prescribing — will be set when the FDA approves Lilly's NDA, which the company has guided to late 2026 / early 2027 with FDA action expected 2027–2028. Until then, retatrutide is available only through enrolled clinical trials; any other source is operating outside the FDA-approved supply chain.